UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2012
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
YES X
NO ___
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
YES X
NO ___
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):
Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES ____
NO X
At November 5, 2012, 7,362,573,528 shares of the issuer s voting common stock were outstanding.
Table of Contents
FORM 10-Q
For the Quarterly Period Ended
September 30, 2012
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three and nine months ended September 30, 2012 and October 2, 2011
Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 30, 2012 and October 2, 2011
Condensed Consolidated Balance Sheets as of September 30, 2012 and December 31, 2011
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2012 and October 2, 2011
Notes to Condensed Consolidated Financial Statements
Review Report of Independent Registered Public Accounting Firm
50
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
51
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
95
Item 4.
Controls and Procedures
95
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
96
Item 1A.
Risk Factors
96
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
97
Item 3.
Defaults Upon Senior Securities
97
Item 4.
Mine Safety Disclosures
97
Item 5.
Other Information
97
Item 6.
Exhibits
98
Signature
99
Table of Contents
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
Nine Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
September 30,
2012
October 2,
2011
September 30,
2012
October 2,
2011
Revenues
13,976
16,609
43,918
49,118
Costs and expenses:
Cost of sales(a)
2,665
3,409
8,162
10,449
Selling, informational and administrative expenses(a)
3,847
4,457
11,801
13,635
Research and development expenses(a)
1,981
2,176
5,734
6,487
Amortization of intangible assets
1,228
1,389
3,939
4,138
Restructuring charges and certain acquisition-related costs
302
1,090
1,089
2,458
Other deductions net
962
547
3,283
1,802
Income from continuing operations before provision for taxes on income
2,991
3,541
9,910
10,149
Provision/(benefit) for taxes on income
(119
1,216
1,882
3,167
Income from continuing operations
3,110
2,325
8,028
6,982
Discontinued operations:
Income from discontinued operations net of tax
104
96
249
303
Gain on sale of discontinued operations net of tax
1,328
1,316
Discontinued operations net of tax
104
1,424
249
1,619
Net income before allocation to noncontrolling interests
3,214
3,749
8,277
8,601
Less: Net income attributable to noncontrolling interests
11
22
31
Net income attributable to Pfizer Inc.
3,208
3,738
8,255
8,570
Earnings per common share basic:(b)
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.42
0.30
1.07
0.88
Discontinued operations net of tax
0.01
0.18
0.03
0.21
Net income attributable to Pfizer Inc. common shareholders
0.43
0.48
1.10
1.09
Earnings per common share diluted:(b)
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.41
0.30
1.06
0.88
Discontinued operations net of tax
0.01
0.18
0.03
0.20
Net income attributable to Pfizer Inc. common shareholders
0.43
0.48
1.09
1.08
Weighted-average shares Basic
7,436
7,770
7,483
7,877
Weighted-average shares Diluted
7,508
7,810
7,550
7,925
Cash dividends paid per common share
0.22
0.20
0.66
0.60
(a)
Exclusive of amortization of intangible assets, except as disclosed in Note 9B. Goodwill and Other Intangible Assets: Other Intangible Assets.
(b)
EPS amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
Table of Contents
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended
Nine Months Ended
(MILLIONS OF DOLLARS)
September 30,
2012
October 2,
2011
September 30,
2012
October 2,
2011
Net income before allocation to noncontrolling interests
3,214
3,749
8,277
8,601
Other Comprehensive Income/(Loss)
Foreign currency translation adjustments
153
(1,565
2,546
Reclassification adjustments(a)
(130
(137
153
(130
(1,565
2,409
Unrealized holding gains/(losses) on derivative financial instruments
446
(1,051
217
(516
Reclassification adjustments for realized (gains)/losses(a)
(221
653
(95
(81
225
(398
122
(597
Unrealized holding gains/(losses) on available-for-sale securities
35
(74
127
(94
Reclassification adjustments for realized (gains)/losses(a)
(9
23
24
32
26
(51
151
(62
Benefit plans: Actuarial gains/(losses)
(88
(592
Reclassification adjustments related to amortization(b)
121
68
351
208
Reclassification adjustments related to curtailments and settlements, net(b)
48
85
160
258
Other
(36
(20
18
(164
45
134
(63
306
Benefit plans: Prior service credits/(costs) and other
(3
23
Reclassification adjustments related to amortization(b)
(19
(17
(53
(52
Reclassification adjustments related to curtailments and settlements, net(b)
(4
(16
(86
(49
Other
(4
(22
(33
(116
(104
Other comprehensive income/(loss), before tax
427
(478
(1,471
1,952
Tax provision/(benefit) on other comprehensive income/(loss)(c)
73
(216
72
(276
Other comprehensive income/(loss) before allocation to noncontrolling interests
354
(262
(1,543
2,228
Comprehensive Income
Comprehensive income before allocation to noncontrolling interests
3,568
3,487
6,734
10,829
Less: Comprehensive income attributable to noncontrolling interests
35
Comprehensive income attributable to Pfizer Inc.
3,563
3,480
6,731
10,794
(a)
Reclassified into Other deductions net in the condensed consolidated statements of income.
(b)
Generally reclassified into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate in the condensed consolidated statements of income.
(c)
See Note 5B. Tax Matters: Taxes on Items of Other Comprehensive Income/(Loss).
See Notes to Condensed Consolidated Financial Statements.
Table of Contents
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS OF DOLLARS)
September 30,
2012
December 31,
2011
(Unaudited)
Assets
Cash and cash equivalents
4,506
3,182
Short-term investments
18,462
23,270
Accounts receivable, less allowance for doubtful accounts
12,523
13,058
Inventories
7,516
6,610
Taxes and other current assets
8,849
9,380
Assets of discontinued operations and other assets held for sale
5,271
5,317
Total current assets
57,127
60,817
Long-term investments
13,429
9,814
Property, plant and equipment, less accumulated depreciation
14,606
15,921
Goodwill
44,370
44,569
Identifiable intangible assets, less accumulated amortization
47,209
51,184
Taxes and other noncurrent assets
5,862
5,697
Total assets
182,603
188,002
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt
7,774
4,016
Accounts payable
2,967
3,678
Dividends payable
1,796
Income taxes payable
1,788
1,009
Accrued compensation and related items
1,736
2,120
Other current liabilities
13,455
15,066
Liabilities of discontinued operations
1,410
1,224
Total current liabilities
29,131
28,909
Long-term debt
31,083
34,926
Pension benefit obligations
6,560
6,341
Postretirement benefit obligations
3,309
3,344
Noncurrent deferred tax liabilities
19,133
18,861
Other taxes payable
6,011
6,886
Other noncurrent liabilities
5,261
6,114
Total liabilities
100,488
105,381
Commitments and Contingencies
Preferred stock
41
45
Common stock
447
445
Additional paid-in capital
72,317
71,423
Employee benefit trusts
(2
(3
Treasury stock
(36,703
(31,801
Retained earnings
51,256
46,210
Accumulated other comprehensive loss
(5,653
(4,129
Total Pfizer Inc. shareholders equity
81,703
82,190
Equity attributable to noncontrolling interests
412
431
Total equity
82,115
82,621
Total liabilities and equity
182,603
188,002
See Notes to Condensed Consolidated Financial Statements.
Table of Contents
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Nine Months Ended
(MILLIONS OF DOLLARS)
September 30,
2012
October 2,
2011
Operating Activities
Net income before allocation to noncontrolling interests
8,277
8,601
Adjustments to reconcile net income before allocation to noncontrolling interests to net
cash provided by operating activities:
Depreciation and amortization
5,716
6,568
Share-based compensation expense
362
347
Asset write-offs and impairment charges
865
773
Gain on sale of discontinued operations
(1,683
Deferred taxes from continuing operations
97
693
Other deferred taxes
23
145
Benefit plan contributions (in excess of)/less than expense
86
(270
Other non-cash adjustments, net
(118
(93
Other changes in assets and liabilities, net of acquisitions and divestitures
(3,510
(102
Net cash provided by operating activities
11,798
14,979
Investing Activities
Purchases of property, plant and equipment
(833
(1,062
Purchases of short-term investments
(14,587
(13,457
Proceeds from redemptions and sales of short-term investments
19,377
7,221
Net proceeds from redemptions and sales of short-term investments with
original maturities of 90 days or less
1,483
10,648
Purchases of long-term investments
(8,694
(3,646
Proceeds from redemptions and sales of long-term investments
3,357
2,001
Acquisitions, net of cash acquired
(782
(3,188
Proceeds from sale of business
2,376
Other investing activities
(4
408
Net cash provided by/(used in) investing activities
(683
1,301
Financing Activities
Proceeds from short-term borrowings
5,700
9,613
Principal payments on short-term borrowings
(3
(3,826
Net payments on short-term borrowings with original maturities of 90 days or less
(6,055
(6,243
Principal payments on long-term debt
(14
(3,486
Purchases of common stock
(4,834
(5,789
Cash dividends paid
(4,915
(4,710
Other financing activities
355
84
Net cash used in financing activities
(9,766
(14,357
Effect of exchange-rate changes on cash and cash equivalents
(25
48
Net increase in cash and cash equivalents
1,324
1,971
Cash and cash equivalents, beginning
3,182
1,735
Cash and cash equivalents, end
4,506
3,706
Supplemental Cash Flow Information
Cash paid during the period for:
Income taxes
1,895
1,539
Interest
1,675
1,872
See Notes to Condensed Consolidated Financial Statements
Table of Contents
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
We prepared the condensed consolidated financial statements following the requirements of the U.S. Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted.
Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three and nine months ended August 26, 2012, and August 28, 2011. We have made certain reclassification adjustments to conform prior-period amounts to the current presentation, primarily related to certain inventories (see Note 8. Inventories) and the reclassification of certain investments (see Note 7. Financial Instruments).
On August 13, 2012, we filed a registration statement with the SEC for the potential initial public offering (IPO) of up to a 20% ownership stake in our Animal Health business, Zoetis Inc. (Zoetis).
On April 23, 2012, we announced that we entered into an agreement to sell our Nutrition business to Nestl . As a result, beginning in the second quarter of 2012, we report the operating results of the Nutrition business as Discontinued operations net of tax in the condensed consolidated statements of income for all periods presented. In addition, the assets and liabilities associated with this business are reported as Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate, in the condensed consolidated balance sheets (see Note 2B. Acquisitions and Divestitures: Divestitures).
On August 1, 2011, we completed the sale of our Capsugel business. The operating results and the gain on the sale of this business are reported as Discontinued operations net of tax in the condensed consolidated statements of income for the three and nine months ended October 2, 2011 (see Note 2B. Acquisitions and Divestitures: Divestitures).
On January 31, 2011, we acquired King Pharmaceuticals, Inc. (King) and in accordance with our domestic and international reporting periods, our condensed consolidated financial statements for the nine months ended October 2, 2011 reflect approximately eight months of King s U.S. operations and approximately seven months of King s international operations (for additional information, see Note 2A. Acquisitions and Divestitures: Acquisitions).
Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and results of operations.
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2011 Annual Report on Form 10-K.
B. Adoption of New Accounting Standards
The provisions of the following new accounting and disclosure standards were adopted as of January 1, 2012:
Presentation of comprehensive income in financial statements. As a result of adopting this new standard, we have presented separate Condensed Consolidated Statements of Comprehensive Income.
An amendment to the guidelines on the measurement and disclosure of fair value that is consistent between U.S. GAAP and International Financial Reporting Standards. The adoption of this new standard did not have a significant impact on our financial statements.
Table of Contents
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
C. Fair Value
Our fair value methodologies depend on the following types of inputs:
Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).
Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs).
Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).
A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
Note 2. Acquisitions and Divestitures
A. Acquisitions
Nexium Over-the-Counter Rights
On August 13, 2012, we announced that we entered into an agreement with AstraZeneca for the over-the-counter (OTC) rights for Nexium, a leading prescription drug currently approved to treat the symptoms of gastroesophageal reflux disease. Under the terms of the agreement, we acquired the exclusive global rights to market Nexium for the approved OTC indications. We made an upfront payment of $250 million to AstraZeneca, and AstraZeneca is eligible to receive milestone payments of up to $550 million based on product launches and level of sales as well as royalty payments based on sales. The upfront payment was expensed and included in Research and development expenses in our condensed consolidated statements of income. A marketing authorization application for OTC Nexium in a 20 mg tablet form was filed with the European Medicines Agency in June 2012. A new drug application filing for OTC Nexium in the U.S. in a 20 mg delayed-release capsule is targeted for the first half of 2013.
Alacer Corp.
On February 26, 2012, we completed our acquisition of Alacer Corp., a privately owned company that manufactures, markets and distributes Emergen-C, a line of effervescent, powdered drink mix vitamin supplements that is the largest-selling branded vitamin C line in the U.S. In connection with this consumer healthcare acquisition, we recorded $247 million in Identifiable intangible assets, consisting primarily of the Emergen-C indefinite-lived brand, $94 million in net deferred tax liabilities and $151 million in Goodwill. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has been finalized.
Ferrosan Holding A/S
On December 1, 2011, we completed our acquisition of the consumer healthcare business of Ferrosan Holding A/S (Ferrosan), a Danish company engaged in the sale of science-based consumer healthcare products, including dietary supplements and lifestyle products, primarily in the Nordic region and the emerging markets of Russia and Central and Eastern Europe. Due to the fact that financial information included in our fiscal year 2011 consolidated financial statements for our subsidiaries operating outside the U.S. is as of and for the year ended November 30, this acquisition is reflected in our condensed consolidated financial statements beginning in the first fiscal quarter of 2012. Our acquisition of Ferrosan s consumer healthcare business increases our presence in dietary supplements with a new set of brands and pipeline products. Also, we believe that the acquisition allows us to expand the marketing of Ferrosan s brands through Pfizer s global footprint and provide greater distribution and scale for certain Pfizer brands, such as Centrum and Caltrate, in Ferrosan s key markets. In connection with this acquisition, we recorded $463 million in Identifiable intangible assets, consisting of indefinite-lived and finite-lived brands, $119 million in net deferred tax liabilities and $246 million in Goodwill. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not been finalized.
Table of Contents
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
King Pharmaceuticals, Inc.
On January 31, 2011 (the acquisition date), we completed a tender offer for the outstanding shares of common stock of King at a purchase price of $14.25 per share in cash and acquired approximately 92.5% of the outstanding shares. On February 28, 2011, we acquired all of the remaining shares of King for $14.25 per share in cash. As a result, the total fair value of consideration transferred for King was approximately $3.6 billion in cash ($3.2 billion, net of cash acquired).
King s principal businesses consist of a prescription pharmaceutical business focused on delivering new formulations of pain treatments designed to discourage common methods of misuse and abuse; the Meridian auto-injector business for emergency drug delivery, which develops and manufactures the EpiPen; an established products portfolio; and an animal health business that offers a variety of feed-additive products for a wide range of species.
The following table provides the assets acquired and liabilities assumed from King:
(MILLIONS OF DOLLARS)
Amounts
Recognized as of
Acquisition Date
(Final)
Working capital, excluding inventories
155
Inventories
340
Property, plant and equipment
412
Identifiable intangible assets, excluding in-process research and development
1,806
In-process research and development
303
Net tax accounts
(328
All other long-term assets and liabilities, net
102
Total identifiable net assets
2,790
Goodwill(a)
765
Net assets acquired/total consideration transferred
3,555
(a)
Goodwill recorded as of the acquisition date totaled $720 million for our three biopharmaceutical operating segments and $45 million for our Animal Health operating segment. (Since the acquisition of King, we have revised our operating segments. See Note 13A. Segment, Geographic and Other Revenue Information: Segment Information.)
As of the acquisition date, the fair value of accounts receivable approximated the book value acquired. The gross contractual amount receivable was $200 million, virtually all of which was expected to be collected.
Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recorded as part of the acquisition of King includes the following:
the expected synergies and other benefits that we believed would result from combining the operations of King with the operations of Pfizer;
any intangible assets that did not qualify for separate recognition, as well as future, yet unidentified projects and products; and
the value of the going-concern element of King s existing businesses (the higher rate of return on the assembled collection of net assets versus if Pfizer had acquired all of the net assets separately).
Goodwill is not amortized and is not deductible for income tax purposes (see Note 9A. Goodwill and Other Intangible Assets: Goodwill for additional information).
The assets and liabilities arising from contingencies recognized as of the acquisition date are not significant to Pfizer s condensed consolidated financial statements.
Table of Contents
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Revenues from King are included in Pfizer's condensed consolidated statements of income from the acquisition date, January 31, 2011, through Pfizer s domestic and international quarter-ends and were $938 million in the first nine months of 2011. We are not able to provide the results of operations attributable to King in the first nine months of 2011 as those operations had been substantially integrated into the larger Pfizer operation shortly after the acquisition.
If the acquisition of King had occurred on January 1, 2011, the change to Pfizer s Revenues, Income from continuing operations attributable to Pfizer Inc. common shareholders and Diluted earnings per share attributable to Pfizer Inc. common shareholders for the first nine months of 2011 would not have been significant.
B. Divestitures
On April 23, 2012, we announced that we entered into an agreement to sell our Nutrition business to Nestl for $11.85 billion in cash. The transaction is expected to close in the next few months, assuming the receipt of the required regulatory clearances and satisfaction of other closing conditions. Beginning in the second quarter of 2012, we report the operating results of the Nutrition business as Discontinued operations net of tax in the condensed consolidated statements of income for all periods presented. The transaction also includes the sale of certain prenatal multivitamins currently commercialized by the Pfizer Consumer Healthcare business unit. The operating results of this product line are also included in Discontinued operations net of tax for all periods presented. In addition, the assets and liabilities associated with the discontinued operations are classified as Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate, in the condensed consolidated balance sheets.
On August 1, 2011, we completed the sale of our Capsugel business for approximately $2.4 billion in cash. The operating results and the gain on the sale of this business are reported as Discontinued operations net of tax in the condensed consolidated statements of income for the three and nine months ended October 2, 2011.
The following table provides the components of Discontinued operations net of tax:
Three Months Ended
Nine Months Ended
(MILLIONS OF DOLLARS)
September 30,
2012
October 2,
2011
September 30,
2012
October 2,
2011
Revenues(a)
564
699
1,665
2,068
Pre-tax income from discontinued operations
129
121
365
397
Provision for taxes on income(b)
25
25
116
94
Income from discontinued operations net of tax
104
96
249
303
Pre-tax gain on sale of discontinued operations
1,695
1,683
Provision for taxes on income(c)
367
367
Gain on sale of discontinued operations net of tax
1,328
1,316
Discontinued operations net of tax(a)
104
1,424
249
1,619
(a)
Includes the Nutrition business for all periods presented and the Capsugel business for 2011 only.
(b)
Includes deferred tax expense of $9 million and a deferred tax benefit of $10 million for the three months ended September 30, 2012 and October 2, 2011, respectively, and a deferred tax expense of $23 million and a deferred tax benefit of $17 million for the nine months ended September 30, 2012 and October 2, 2011, respectively. These deferred tax provisions include deferred income taxes related to investments in certain foreign subsidiaries resulting from our intention not to hold these subsidiaries permanently.
(c)
Includes deferred tax expense of $162 million for the three and nine months ended October 2, 2011. These deferred tax provisions include deferred taxes on certain current-year funds earned outside the U.S. that will not be permanently reinvested overseas.
10
Table of Contents
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
The following table provides the components of Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations: